Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study

Alexander Balck; Bandik Föh; Max Borsche; Johann Rahmöller; Eva-Juliane Vollstedt; Frederike Waldeck; Nadja Käding; Christoph Twesten; Alexander Mischnik; Gabriele Gillessen-Kaesbach; Marc Ehlers; Christian Sina; Stefan Taube; Hauke Busch; Jan Rupp; Alexander Katalinic; Christine Klein

doi:10.1186/s12889-022-13666-z

Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study

Alexander Balck, Bandik Föh, Max Borsche, Johann Rahmöller, Eva-Juliane Vollstedt, Frederike Waldeck, Nadja Käding, Christoph Twesten, Alexander Mischnik, Gabriele Gillessen-Kaesbach, Marc Ehlers, Christian Sina, Stefan Taube, Hauke Busch, Jan Rupp, Alexander Katalinic, Christine Klein

Abstract

BACKGROUND: Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life.

METHODS: The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and/or infection and post-COVID-19 symptoms.

DISCUSSION: The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases.

TRIAL REGISTRATION: DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00023418 , Registered on 28 October 2020.

Originalsprache	Englisch
Aufsatznummer	1305
Zeitschrift	BMC Public Health
Jahrgang	22
Ausgabenummer	1
Seiten (von - bis)	1305
ISSN	1471-2458
DOIs	https://doi.org/10.1186/s12889-022-13666-z
Publikationsstatus	Veröffentlicht - 07.07.2022

Strategische Forschungsbereiche und Zentren

Profilbereich: Zentrum für Bevölkerungsmedizin und Versorgungsforschung (ZBV)

Coronavirus-Bezug

Forschung zu SARS-CoV-2 / COVID-19

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dokumente

10.1186/s12889-022-13666-z

Weitere Links

ELISA: LübEcker Längsschnittuntersuchung zu Infektionen mit SARS –CoV-2
Klein, C. (Projektleiter*in (PI)), Rupp, J. (Projektleiter*in (PI)) & Katalinic, A. (Projektleiter*in (PI))
01.04.20 → 31.03.23
Projekt: Projekte aus Bundesmitteln › Projekte aus Mitteln der Bundesministerien: BMBF

Zitieren

Balck, A., Föh, B., Borsche, M., Rahmöller, J., Vollstedt, E.-J., Waldeck, F., Käding, N., Twesten, C., Mischnik, A., Gillessen-Kaesbach, G., Ehlers, M., Sina, C., Taube, S., Busch, H., Rupp, J., Katalinic, A., & Klein, C. (2022). Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study. BMC Public Health, 22(1), 1305. Artikel 1305. https://doi.org/10.1186/s12889-022-13666-z

@article{0bab7f14c8a749a594478bf41960d017,

title = "Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study",

abstract = "BACKGROUND: Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life.METHODS: The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and/or infection and post-COVID-19 symptoms.DISCUSSION: The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases.TRIAL REGISTRATION: DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00023418 , Registered on 28 October 2020.",

author = "Alexander Balck and Bandik F{\"o}h and Max Borsche and Johann Rahm{\"o}ller and Eva-Juliane Vollstedt and Frederike Waldeck and Nadja K{\"a}ding and Christoph Twesten and Alexander Mischnik and Gabriele Gillessen-Kaesbach and Marc Ehlers and Christian Sina and Stefan Taube and Hauke Busch and Jan Rupp and Alexander Katalinic and Christine Klein",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = jul,

day = "7",

doi = "10.1186/s12889-022-13666-z",

language = "English",

volume = "22",

pages = "1305",

journal = "BMC Public Health",

issn = "1471-2458",

number = "1",

}

Balck, A, Föh, B, Borsche, M, Rahmöller, J , Vollstedt, E-J , Waldeck, F , Käding, N, Twesten, C, Mischnik, A, Gillessen-Kaesbach, G, Ehlers, M , Sina, C , Taube, S , Busch, H , Rupp, J , Katalinic, A & Klein, C 2022, 'Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study', BMC Public Health, Jg. 22, Nr. 1, 1305, S. 1305. https://doi.org/10.1186/s12889-022-13666-z

TY - JOUR

T1 - Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study

AU - Balck, Alexander

AU - Föh, Bandik

AU - Borsche, Max

AU - Rahmöller, Johann

AU - Vollstedt, Eva-Juliane

AU - Waldeck, Frederike

AU - Käding, Nadja

AU - Twesten, Christoph

AU - Mischnik, Alexander

AU - Gillessen-Kaesbach, Gabriele

AU - Ehlers, Marc

AU - Sina, Christian

AU - Taube, Stefan

AU - Busch, Hauke

AU - Rupp, Jan

AU - Katalinic, Alexander

AU - Klein, Christine

PY - 2022/7/7

Y1 - 2022/7/7

N2 - BACKGROUND: Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life.METHODS: The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and/or infection and post-COVID-19 symptoms.DISCUSSION: The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases.TRIAL REGISTRATION: DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00023418 , Registered on 28 October 2020.

AB - BACKGROUND: Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life.METHODS: The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and/or infection and post-COVID-19 symptoms.DISCUSSION: The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases.TRIAL REGISTRATION: DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00023418 , Registered on 28 October 2020.

UR - http://www.scopus.com/inward/record.url?scp=85133639133&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/379302f8-b72d-34c5-b4c2-22536fb205fa/

U2 - 10.1186/s12889-022-13666-z

DO - 10.1186/s12889-022-13666-z

M3 - Journal articles

C2 - 35799167

SN - 1471-2458

VL - 22

SP - 1305

JO - BMC Public Health

JF - BMC Public Health

IS - 1

M1 - 1305

ER -

Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study

Abstract

Strategische Forschungsbereiche und Zentren

Coronavirus-Bezug

UN SDGs

Dokumente

Weitere Links

Fingerprint

Projekte

ELISA: LübEcker Längsschnittuntersuchung zu Infektionen mit SARS –CoV-2

Zitieren